These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31094905)

  • 1. MYCN Amplified Relapse Following Resolution of MYCN Nonamplified 4S Neuroblastoma With Placental Involvement: A Case Report and Review of the Literature.
    Langenberg-Ververgaert KPS; Renzi S; Chung CT; Shago M; Lo W; Davidson S; Villani A; Baruchel S; Irwin MS; Morgenstern DA
    J Pediatr Hematol Oncol; 2019 Jul; 41(5):388-391. PubMed ID: 31094905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
    Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma.
    Hungate EA; Applebaum MA; Skol AD; Vaksman Z; Diamond M; McDaniel L; Volchenboum SL; Stranger BE; Maris JM; Diskin SJ; Onel K; Cohn SL
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 29117357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.
    Jeison M; Ash S; Halevy-Berko G; Mardoukh J; Luria D; Avigad S; Feinberg-Gorenshtein G; Goshen Y; Hertzel G; Kapelushnik J; Ben Barak A; Attias D; Steinberg R; Stein J; Stark B; Yaniv I
    Am J Pathol; 2010 Jun; 176(6):2616-25. PubMed ID: 20395439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
    Marrano P; Irwin MS; Thorner PS
    Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct Targeting of
    Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group.
    Kawano A; Hazard FK; Chiu B; Naranjo A; LaBarre B; London WB; Hogarty MD; Cohn SL; Maris JM; Park JR; Gastier-Foster JM; Ikegaki N; Shimada H
    Am J Surg Pathol; 2021 Aug; 45(8):1075-1081. PubMed ID: 33739795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable
    Ambros IM; Tonini GP; Pötschger U; Gross N; Mosseri V; Beiske K; Berbegall AP; Bénard J; Bown N; Caron H; Combaret V; Couturier J; Defferrari R; Delattre O; Jeison M; Kogner P; Lunec J; Marques B; Martinsson T; Mazzocco K; Noguera R; Schleiermacher G; Valent A; Van Roy N; Villamon E; Janousek D; Pribill I; Glogova E; Attiyeh EF; Hogarty MD; Monclair TF; Holmes K; Valteau-Couanet D; Castel V; Tweddle DA; Park JR; Cohn S; Ladenstein R; Beck-Popovic M; De Bernardi B; Michon J; Pearson ADJ; Ambros PF
    J Clin Oncol; 2020 Nov; 38(31):3685-3697. PubMed ID: 32903140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
    Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
    Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of stage 4S composite neuroblastoma with a MYCN-amplified nodule.
    Bishop MW; Yin H; Shimada H; Towbin AJ; Miethke A; Weiss B
    J Pediatr Hematol Oncol; 2014 Jan; 36(1):e31-5. PubMed ID: 23528904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.
    Berbegall AP; Bogen D; Pötschger U; Beiske K; Bown N; Combaret V; Defferrari R; Jeison M; Mazzocco K; Varesio L; Vicha A; Ash S; Castel V; Coze C; Ladenstein R; Owens C; Papadakis V; Ruud E; Amann G; Sementa AR; Navarro S; Ambros PF; Noguera R; Ambros IM
    Br J Cancer; 2018 May; 118(11):1502-1512. PubMed ID: 29755120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of the MYCN oncogene in neuroblastoma.
    Theissen J; Boensch M; Spitz R; Betts D; Stegmaier S; Christiansen H; Niggli F; Schilling F; Schwab M; Simon T; Westermann F; Berthold F; Hero B
    Clin Cancer Res; 2009 Mar; 15(6):2085-90. PubMed ID: 19276282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variation associated with childhood and adult stature and risk of MYCN-amplified neuroblastoma.
    Semmes EC; Shen E; Cohen JL; Zhang C; Wei Q; Hurst JH; Walsh KM
    Cancer Med; 2020 Nov; 9(21):8216-8225. PubMed ID: 32945147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells.
    Yamashita K; Kiyonari S; Tsubota S; Kishida S; Sakai R; Kadomatsu K
    Cancer Sci; 2020 Jul; 111(7):2431-2439. PubMed ID: 32415892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and characterization of a novel MDM2/MYCN-co-amplified neuroblastoma cell line, NBN-SHIM, established from a late recurrent stage MS tumor.
    Kato K; Nagai JI; Goto H; Shinkai M; Kitagawa N; Toyoda Y; Nishi T; Kigasawa H; Tanaka M; Kurosawa K; Ito Y; Haruta M; Kamijo T; Yoshimi A; Tsuchida M; Nagahara N; Tanaka Y
    Hum Cell; 2024 Sep; 37(5):1602-1609. PubMed ID: 39080217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy.
    Yanishevski D; McCarville MB; Doubrovin M; Spiegl HR; Zhao X; Lu Z; Federico SM; Furman WL; Murphy AJ; Davidoff AM
    J Pediatr Surg; 2020 Jan; 55(1):130-134. PubMed ID: 31685267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
    Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired Antitumor Immune Response in
    Kacher J; Manches O; Aspord C; Sartelet H; Chaperot L
    Cancer Res Commun; 2022 Jul; 2(7):577-589. PubMed ID: 36923280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.